Edition:
United Kingdom

Nektar Therapeutics (NKTR.OQ)

NKTR.OQ on NASDAQ Stock Exchange Global Select Market

84.51USD
24 Apr 2018
Change (% chg)

$-0.94 (-1.10%)
Prev Close
$85.45
Open
$86.14
Day's High
$87.00
Day's Low
$83.11
Volume
648,439
Avg. Vol
1,070,862
52-wk High
$111.36
52-wk Low
$17.33

Chart for

About

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and... (more)

Overall

Beta: 1.38
Market Cap(Mil.): $3,878.49
Shares Outstanding(Mil.): 156.33
Dividend: --
Yield (%): --

Financials

  NKTR.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -1.40 -- --
ROI: -53.15 1.58 14.38
ROE: -- 2.41 16.07

BRIEF-Nektar And Takeda To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, And Tak-659, In Liquid And Solid Tumors

* NEW ONCOLOGY CLINICAL COLLABORATION BETWEEN NEKTAR AND TAKEDA TO EVALUATE COMBINATION OF NKTR-214, A CD122-BIASED AGONIST, AND TAK-659, A DUAL SYK AND FLT-3 INHIBITOR, IN LIQUID AND SOLID TUMORS

24 Apr 2018

BRIEF-Nektar Therapeutics Q4 Loss Per Share $0.21

* Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon: Further company coverage:

01 Mar 2018

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion(1.33 billion pounds) for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

Bristol-Myers to pay $1.85 billion in cancer deal with Nektar

Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

UPDATE 1-Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion for a global development and profit-sharing deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

Bristol-Myers to pay $1.85 bln in cancer deal with Nektar

Feb 14 Bristol-Myers Squibb Co will pay Nektar Therapeutics $1.85 billion in cash and share purchase for a global development and commercialization deal on a promising Nektar cancer drug, the companies announced on Wednesday.

14 Feb 2018

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Bayer Of Co-Development, License, Co-Promotion Agreement

* NEKTAR THERAPEUTICS - ‍ON DEC 14, CO RECEIVED NOTICE OF TERMINATION FROM BAYER OF CO-DEVELOPMENT, LICENSE,CO-PROMOTION AGREEMENT, DATED AUG 1, 2007​ Source text: (http://bit.ly/2BsgSdG) Further company coverage:

15 Dec 2017

BRIEF-Nektar Therapeutics Says Received Notice Of Termination From Daiichi Of Collaboration Agreement

* NEKTAR THERAPEUTICS - ON DEC 6, CO RECEIVED NOTICE OF TERMINATION FROM DAIICHI OF COLLABORATION AGREEMENT WHICH WILL BECOME EFFECTIVE AS OF FEB 4, 2018

12 Dec 2017

BRIEF-Nektar Therapeutics estimates wind down costs of $3 mln to $4 mln related to ceasing clinical program

* Nektar Therapeutics says estimates that it will incur about $3 million to $4 million of wind-down costs

24 Nov 2017

BRIEF-EMA recommends against approval after re-examination of Nektar's drug onzeald

* EU MEDICINES AGENCY RECOMMENDS AGAINST APPROVAL AFTER RE-EXAMINATION OF NEKTAR'S DRUG ONZEALD FOR TREATMENT OF BREAST CANCER WHICH HAS SPREAD TO BRAIN‍​ Source text (http://bit.ly/2zxBcXv) Further company coverage:

10 Nov 2017

Earnings vs. Estimates